Sevelamer Is Cost-Saving vs. Calcium Carbonate in Non-Dialysis-Dependent CKD Patients in Italy: A Patient-Level Cost-Effectiveness Analysis of the INDEPENDENT Study

• DOI: 10.1159/000365746
• Publication Date: 2014-08-27T06:14:42Z
• Authors: Matteo Ruggeri; Filippo Cipriani; Antonio Bellasi; Domenico Russo; Biagio Di Iorio; S. Springer Healt...
• Keywords: Male; Time Factors; Cost-Benefit Analysis; HEALTH ECONOMICS; Chronic kidney disease · Hyperphosphatemia · Sevelamer · Calcium carbonate · Cost-effectiveness; Sevelamer; Health Care Costs; Middle Aged; Calcium Carbonate; 3. Good health; Hyperphosphatemia; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Cause of Death; Polyamines; Humans; Female; Mortality; Renal Insufficiency, Chronic; Aged; Chelating Agents

<b><i>Objectives:</i></b> To conduct a cost-effectiveness analysis of sevelamer versus calcium carbonate in patients with non-dialysis-dependent CKD (NDD-CKD) from the Italian NHS perspective using patient-level data from the INDEPENDENT-CKD study. <b><i>Methods:</i></b> Patient-level data on all-cause mortality, dialysis inception and phosphate binder dose were obtained for all 107 sevelamer and 105 calcium carbonate patients from the INDEPENDENT-CKD study. Hospitalization and frequency of dialysis data were collected post hoc for all patients via a retrospective chart review. Phosphate binder, hospitalization, and dialysis costs were expressed in 2012 euros using hospital pharmacy, Italian diagnosis-related group and ambulatory tariffs, respectively. Total life years (LYs) and costs per treatment group were calculated for the 3-year period of the study. Bootstrapping was used to estimate confidence intervals around outcomes, costs, and cost-effectiveness and to calculate the cost-effectiveness acceptability curve. A subgroup analysis of patients who did not initiate dialysis during the INDEPENDENT-CKD study was also conducted. <b><i>Results:</i></b> Sevelamer was associated with 0.06 additional LYs (95% CI -0.04 to 0.16) and cost savings of EUR -5,615 (95% CI -10,066 to -1,164) per patient compared with calcium carbonate. On the basis of the bootstrap analysis, sevelamer was dominant compared to calcium carbonate in 87.1% of 10,000 bootstrap replicates. Similar results were observed in the subgroup analysis. Results were driven by a significant reduction in all-cause mortality and significantly fewer hospitalizations in the sevelamer group, which offset the higher acquisition cost for sevelamer. <b><i>Conclusions:</i></b> Sevelamer provides more LYs and is less costly than calcium carbonate in patients with NDD-CKD in Italy.